These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 9620905

  • 21. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
    Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ.
    Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):413-7. PubMed ID: 8756815
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
    Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV.
    Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
    Hansen G, Hoffjan S, Mosler K, Schuster A.
    Lung; 2001 Jul; 179(3):185-94. PubMed ID: 11891608
    [Abstract] [Full Text] [Related]

  • 27. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
    Homnick DN, Marks JH, Rubin BK.
    J Aerosol Med; 2007 Jul; 20(1):45-9. PubMed ID: 17388752
    [Abstract] [Full Text] [Related]

  • 28. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME.
    N Engl J Med; 1994 Sep 08; 331(10):637-42. PubMed ID: 7503821
    [Abstract] [Full Text] [Related]

  • 29. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME.
    Am J Respir Crit Care Med; 1995 Mar 08; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [Abstract] [Full Text] [Related]

  • 30. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum.
    Shibuya Y, Wills PJ, Cole PJ.
    Respiration; 2001 Mar 08; 68(6):615-9. PubMed ID: 11786718
    [Abstract] [Full Text] [Related]

  • 31. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy.
    App EM, King M, Helfesrieder R, Köhler D, Matthys H.
    Am Rev Respir Dis; 1990 Mar 08; 141(3):605-12. PubMed ID: 2310093
    [Abstract] [Full Text] [Related]

  • 32. Mucus structure and properties in cystic fibrosis.
    Rubin BK.
    Paediatr Respir Rev; 2007 Mar 08; 8(1):4-7. PubMed ID: 17419972
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. RhDNase before airway clearance therapy improves airway patency in children with CF.
    van der Giessen LJ, de Jongste JC, Gosselink R, Hop WC, Tiddens HA.
    Pediatr Pulmonol; 2007 Jul 08; 42(7):624-30. PubMed ID: 17534979
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis.
    Furuya ME, Lezana-Fernández JL, Vargas MH, Hernández-Sierra JF, Ramírez-Figueroa JL.
    Arch Med Res; 2001 Jul 08; 32(1):30-4. PubMed ID: 11282177
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
    Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, Johnson CA, Light MC, Scott SF, Tullis DE.
    Eur Respir J; 1995 Jun 08; 8(6):954-8. PubMed ID: 7589382
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.